Ocular Therapeutix reports Phase 3 SOL-1 wins and plans AXPAXLI NDA in Q4 2026
FROM THE WIRE · FINANCE.YAHOO.COM
This article first appeared on GuruFocus. Cash and Cash Equivalents: $530.6 million as of the end of Q3 2026. Cash Runway: Expected to fund operations into 2028 based on current assumptions, excluding full anticipated expenses of commercializing AXPAXLI. Release Date: November…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive Phase 3 data and a planned regulatory filing can materially move a biotech stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The Phase 3 SOL-1 study showed superiority results for AXPAXLI.
- 02The company plans to submit the NDA for wet AMD in Q4 2026.
- 03Cash stood at $530.6 million, with runway expected into 2028.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets